Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 25;14:29133. doi: 10.1038/s41598-024-72408-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — Upregulation of SLC4A4 in prostate cancer. (A, B) SLC4A4 transcript is highly expressed in several cancers, including prostate adenocarcinoma (PRAD), based on the TCGA study cohort. (C, D) A subset of PRAD showed higher SLC4A4 expression in Gleason score 7, 8, and 9 tumors and this was associated with the overall survival of patients. (E, F) Immunohistochemical (IHC) analysis of primary prostate tumor samples showed higher SLC4A4 protein expression compared to non-tumor tissues. (G, H) Compared to RWPE-1 normal prostate epithelial cells, the SLC4A4 mRNA level was higher in DU145 androgen receptor (AR)-negative prostate cancer (PCa) cells. In AR-positive PCa cells, SLC4A4 mRNA level was elevated in C4-2, followed by VCAP (*P < 0.05). SLC4A4 overexpression was also detected by Western blotting, with PC3 cells having higher SLC4A4 protein level in AR-negative PCa cells. In AR-positive PCa cells, both C4-2 and LNCAP showed higher SLC4A4 protein expression. The results are presented as means ± standard error of three independent experiments.

Fig. 1 — Upregulation of SLC4A4 in prostate cancer. (A, B) SLC4A4 transcript is highly expressed in several cancers, including prostate adenocarcinoma (PRAD), based on the TCGA study cohort. (C, D) A subset of PRAD showed higher SLC4A4 expression in Gleason score 7, 8, and 9 tumors and this was associated with the overall survival of patients. (E, F) Immunohistochemical (IHC) analysis of primary prostate tumor samples showed higher SLC4A4 protein expression compared to non-tumor tissues. (G, H) Compared to RWPE-1 normal prostate epithelial cells, the SLC4A4 mRNA level was higher in DU145 androgen receptor (AR)-negative prostate cancer (PCa) cells. In AR-positive PCa cells, SLC4A4 mRNA level was elevated in C4-2, followed by VCAP (*P < 0.05). SLC4A4 overexpression was also detected by Western blotting, with PC3 cells having higher SLC4A4 protein level in AR-negative PCa cells. In AR-positive PCa cells, both C4-2 and LNCAP showed higher SLC4A4 protein expression. The results are presented as means ± standard error of three independent experiments.